Izencitinib

Izencitinib (TD-1473) is a drug which acts as a pan-Janus kinase inhibitor, binding with high affinity at all three subtypes JAK1, JAK2 and JAK3. It is taken orally and was developed to be gut selective with minimal absorption into the rest of the body, allowing targeting of inflammatory bowel disease but with reduced side effects compared to other similar drugs.^[1][2]

Izencitinib

Identifiers
IUPAC name 3-[(1R,5S)-3-[[7-[(5-methyl-1H-pyrazol-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-8-azabicyclo[3.2.1]octan-8-yl]propanenitrile
CAS Number	2051918-33-1
PubChem CID	124090478
IUPHAR/BPS	10458
DrugBank	DB16660
ChemSpider	75536963
UNII	2ZT81PV5UM
ChEMBL	ChEMBL4650343
Chemical and physical data
Formula	C22H26N8
Molar mass	402.506 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=NN1)NC2=NC(=C3C=CC=NC3=C2)NC4C[C@H]5CC[C@@H](C4)N5CCC#N
InChI InChI=1S/C22H26N8/c1-14-10-21(29-28-14)26-20-13-19-18(4-2-8-24-19)22(27-20)25-15-11-16-5-6-17(12-15)30(16)9-3-7-23/h2,4,8,10,13,15-17H,3,5-6,9,11-12H2,1H3,(H3,25,26,27,28,29)/t15?,16-,17+ Key:DADAEARVGOQWHV-ALOPSCKCSA-N

See also

• Delgocitinib
• Tofacitinib